A phase II randomized study of the virologic and immunologic effect of zidovudine + stavudine versus stavudine alone and zidovudine + lamivudine in patients with >300 CD4 cells who were antiretroviral naive (ACTG 298).

Source:http://linkedlifedata.com/resource/pubmed/id/12167276

AIDS Res. Hum. Retroviruses 2002 Jul 1 18 10 699-704

Download in:

View as

General Info

PMID
12167276